Spanish antenna company Fractus has filed a patent infringement complaint against Resmed alleging its sleep apnoea devices and related connected therapy products infringe multiple Fractus patents.

The complaint (3:25-cv-02680-LL-JLB) was filed in the US District Court for the Southern District of California. It covers miniaturised, high-performance multi-band antenna innovations.

“Fractus has invested for decades in research that enables reliable, compact wireless connectivity across industries,” said Jordi Ilario, chief executive officer of Fractus. “When companies use our patented technology without a licence, we act to protect our intellectual property and ensure a level playing field for innovators who respect IP rights.”

Ruben Bonet, executive chairman of Fractus, added: “Connectivity is increasingly critical in digital health and remote patient monitoring. Our goal is simple: safeguard the value of our inventions so that technology leaders can continue to build on solid, fairly licensed foundations.”

Fractus is represented by Kobre & Kim LLP. The litigation team will be led by Michael Ng, Daniel Zaheer and George Stamatopoulos, seasoned trial lawyers in intellectual property disputes.

“We are honoured to collaborate again with Fractus to return value for its ground-breaking innovations, which have improved the lives of so many people around the world,” said Ng.

Fractus is an early pioneer in the application of geometry and mathematics to antenna design. The company’s patented innovations enable compact, high-performance, multi-band antennas that are widely used across smartphones, IoT devices, network infrastructure and connected health applications.

Fractus holds a portfolio covering more than 40 inventions and its technology has been licensed by global companies. Among other recognitions, Fractus (www.fractus.com) was named a 2005 World Economic Forum Technology Pioneer; its inventors were finalists for the European Inventor Award in 2014; and in 2017 the company received the European Inspiring Company Award from the London Stock Exchange Group.

When asked to respond, Resmed (www.resmed.com) replied: “Resmed does not comment on active litigation. With 35 years of innovation and more than 10,000 pending or issued patents and designs, Resmed is a leader in creating life-changing health technologies that people love. We will defend our innovations to ensure patients continue to receive the high-quality care they expect from us.”